You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClocortolone
Accession NumberDB00838  (APRD00877)
TypeSmall Molecule
GroupsApproved
DescriptionClocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Structure
Thumb
Synonyms
9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione
9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
Clocortolon
Clocortolona
Clocortolone
Clocortolonum
External Identifiers
  • SH 863
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clocortolone Pivalatecream.001 g/gtopicalDr. Reddy's Laboratories Inc2014-02-17Not applicableUs
Clodermcream.001 g/gtopicalCoria Laboratories1977-08-22Not applicableUs
Clodermcream.001 g/gtopicalPromius Pharma, LLC1977-08-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clocortolone acetate
4258-85-9
Thumb
  • InChI Key: ARPLCFGLEYFDCN-CDACMRRYSA-N
  • Monoisotopic Mass: 452.1765799
  • Average Mass: 452.95
DBSALT000939
Clocortolone caproate
4891-71-8
Thumb
  • InChI Key: MMTRTBFDFNRBQO-ANHDKODLSA-N
  • Monoisotopic Mass: 508.2391802
  • Average Mass: 509.06
DBSALT001838
Clocortolone pivalate
34097-16-0
Thumb
  • InChI Key: SXYZQZLHAIHKKY-GSTUPEFVSA-N
  • Monoisotopic Mass: 494.2235301
  • Average Mass: 495.03
DBSALT001365
Categories
UNIIN8ZUB7XE0H
CAS number4828-27-7
WeightAverage: 410.907
Monoisotopic: 410.166015296
Chemical FormulaC22H28ClFO4
InChI KeyInChIKey=YMTMADLUXIRMGX-RFPWEZLHSA-N
InChI
InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14S,15S,17S)-1-chloro-8-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[[email protected]](C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(Cl)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Chlorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alkyl chloride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
PharmacodynamicsLike other topical corticosteroids, clocortolone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Clocortolone is a moderate potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Mechanism of actionThe precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. These enzyme transcriptional changes are mediated by the drug binding first to the glucocorticoid receptor. This complex can migrate to the cell nucleus which then binds to DNA initiating genetic activation and repression of various genes.
Related Articles
AbsorptionTopical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityTopically applied clocortolone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9737
Caco-2 permeable+0.8054
P-glycoprotein substrateSubstrate0.7404
P-glycoprotein inhibitor INon-inhibitor0.7095
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8141
CYP450 2C9 substrateNon-substrate0.8412
CYP450 2D6 substrateNon-substrate0.8977
CYP450 3A4 substrateSubstrate0.7374
CYP450 1A2 substrateNon-inhibitor0.9164
CYP450 2C9 inhibitorNon-inhibitor0.9119
CYP450 2D6 inhibitorNon-inhibitor0.9061
CYP450 2C19 inhibitorNon-inhibitor0.9182
CYP450 3A4 inhibitorInhibitor0.6251
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.857
Ames testNon AMES toxic0.8537
CarcinogenicityNon-carcinogens0.8855
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9619
hERG inhibition (predictor II)Non-inhibitor0.5411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Dow pharmaceutical sciences inc
Packagers
Dosage forms
FormRouteStrength
Creamtopical.001 g/g
Prices
Unit descriptionCostUnit
Cloderm 0.1% Cream 45 gm Tube140.98USD tube
Cloderm 0.1% cream3.64USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.015 mg/mLALOGPS
logP2.73ALOGPS
logP2.47ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity105.74 m3·mol-1ChemAxon
Polarizability41.8 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesD07AB21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (167 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clocortolone.
AldesleukinClocortolone may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Clocortolone can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clocortolone.
AmiodaroneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.
Amphotericin BClocortolone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Clocortolone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Clocortolone can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Clocortolone.
BazedoxifeneThe serum concentration of Clocortolone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideClocortolone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clocortolone.
Bismuth SubcitrateThe bioavailability of Clocortolone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Clocortolone can be increased when it is combined with Boceprevir.
BumetanideClocortolone may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clocortolone.
Calcium carbonateThe bioavailability of Clocortolone can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Clocortolone can be decreased when it is combined with Carbamazepine.
CeritinibClocortolone may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Clocortolone can be increased when it is combined with Ceritinib.
ChlorothiazideClocortolone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Clocortolone can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneClocortolone may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Clocortolone can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Clocortolone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Clocortolone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clocortolone.
CoumaphosThe risk or severity of adverse effects can be increased when Clocortolone is combined with Coumaphos.
DarunavirThe serum concentration of Clocortolone can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Clocortolone is combined with Dichlorvos.
DienestrolThe serum concentration of Clocortolone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Clocortolone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone.
DihydrotestosteroneClocortolone may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Clocortolone is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Edrophonium.
EnzalutamideThe serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Clocortolone can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Clocortolone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Clocortolone can be increased when it is combined with Estrone.
Etacrynic acidClocortolone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Clocortolone can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fenthion.
FluoxymesteroneClocortolone may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Clocortolone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Clocortolone can be decreased when it is combined with Fosphenytoin.
FurosemideClocortolone may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Clocortolone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clocortolone.
HexestrolThe serum concentration of Clocortolone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Clocortolone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clocortolone.
HydrochlorothiazideClocortolone may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideClocortolone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Clocortolone can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Clocortolone.
IndapamideClocortolone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Clocortolone can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Clocortolone.
ItraconazoleThe serum concentration of Clocortolone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Clocortolone can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Clocortolone can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Clocortolone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Clocortolone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Clocortolone is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clocortolone.
MestranolThe serum concentration of Clocortolone can be increased when it is combined with Mestranol.
MethyclothiazideClocortolone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneClocortolone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneClocortolone may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Clocortolone can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Minaprine.
MitotaneThe serum concentration of Clocortolone can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Clocortolone.
NefazodoneThe serum concentration of Clocortolone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Clocortolone can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Neostigmine.
NevirapineThe serum concentration of Clocortolone can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nicorandil.
OxandroloneClocortolone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneClocortolone may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Clocortolone can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Clocortolone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clocortolone.
PhenytoinThe serum concentration of Clocortolone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Physostigmine.
PiretanideClocortolone may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Clocortolone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideClocortolone may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Clocortolone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Clocortolone can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pyridostigmine.
QuinestrolThe serum concentration of Clocortolone can be increased when it is combined with Quinestrol.
QuinethazoneClocortolone may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Clocortolone.
RifabutinThe serum concentration of Clocortolone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Clocortolone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Clocortolone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Clocortolone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clocortolone.
SaquinavirThe serum concentration of Clocortolone can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Clocortolone.
StanozololClocortolone may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Clocortolone.
TelaprevirThe serum concentration of Clocortolone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Clocortolone can be increased when it is combined with Telithromycin.
TestosteroneClocortolone may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Clocortolone can be increased when it is combined with Tibolone.
TorasemideClocortolone may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Clocortolone is combined with Trichlorfon.
TrichlormethiazideClocortolone may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tubocurarine.
VoriconazoleThe serum concentration of Clocortolone can be increased when it is combined with Voriconazole.
WarfarinClocortolone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Clocortolone can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Ali A, Balkovec JM, Greenlee M, Hammond ML, Rouen G, Taylor G, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Forrest MJ, Carballo-Jane E, Luell S, Lowitz K, Visco D: Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat. Bioorg Med Chem. 2008 Aug 15;16(16):7535-42. doi: 10.1016/j.bmc.2008.07.037. Epub 2008 Jul 20. [PubMed:18691892 ]
  2. Buchwald P: Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008 Feb;73(2):193-208. Epub 2007 Oct 11. [PubMed:18022656 ]
  3. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23